{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:13:34Z","timestamp":1791908014064,"version":"4.3.4"},"reference-count":104,"publisher":"Journal of Biological Methods","issue":"3","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HPR"],"abstract":"<jats:p>Purpose of Review\nInsomnia is a complex sleeping disorder that affects the lives of many individuals worldwide. Insomnia often occurs in the presence of coexisting comorbidities making it a complex disorder that requires a multifactorial approach to therapy. First-line therapy is cognitive-behavioral therapy for insomnia (CBT-I). Pharmacotherapy for insomnia falls into four classes based on mechanism of action: benzodiazepine receptor agonists (BZRAs), histamine receptor antagonists, melatonin receptor agonists, and dual orexin receptor antagonists (DORAs).\nRecent Findings\nDaridorexant is a dual orexin type 1 and types 2 (OX1&amp;nbsp;and OX2) receptor antagonist that was recently approved by the US FDA for the treatment of adults suffering from insomnia. It was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep. Daridorexant offers patients relief from insomnia while avoiding the severe side effects and dependency issues of traditional treatments like benzodiazepines and sedatives.\nSummary\nIn this article, we review the most recent data on insomnia treatments and summarize the safety and efficacy of daridorexant in treating insomnia.<\/jats:p>","DOI":"10.52965\/001c.37400","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T21:32:52Z","timestamp":1661808772000},"page":"1","source":"Crossref","is-referenced-by-count":19,"title":["Daridorexant for the Treatment of Insomnia"],"prefix":"10.14440","volume":"10","author":[{"given":"Christopher L","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Supra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"D. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5574","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/0269881119882854","article-title":"Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration","volume":"34","author":"Clemens Muehlan","year":"2020","journal-title":"Journal of Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0269-8811","issn-type":"print"},{"issue":"8","key":"ref2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40261-021-01062-1","article-title":"Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis","volume":"41","author":"Uta Schilling","year":"2021","journal-title":"Clinical Drug Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/1173-2563","issn-type":"print"},{"issue":"6","key":"ref3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cpt.2592","article-title":"Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator","volume":"111","author":"Clemens Muehlan","year":"2022","journal-title":"Clinical Pharmacology & Therapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9236","issn-type":"print"},{"issue":"21","key":"ref4","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/wnl.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Gary Zammit","year":"2020","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsaa275","article-title":"Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea","volume":"44","author":"Marie-Laure Boof","year":"2021","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"2","key":"ref6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: what we know and what we still need to learn","volume":"6","author":"Maurice M. Ohayon","year":"2002","journal-title":"Sleep Medicine Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0792","issn-type":"print"},{"issue":"8","key":"ref7","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.5665\/sleep.3914","article-title":"Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the National Ambulatory Medical Care survey 1999-2010","volume":"37","author":"Earl S. Ford","year":"2014","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"9","key":"ref8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/070674371105600905","article-title":"Prevalence of Insomnia and its Treatment in Canada","volume":"56","author":"Charles M Morin","year":"2011","journal-title":"The Canadian Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0706-7437","issn-type":"print"},{"issue":"9","key":"ref9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.sleep.2009.07.008","article-title":"Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD)","volume":"10","author":"Maurice M. Ohayon","year":"2009","journal-title":"Sleep Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1389-9457","issn-type":"print"},{"issue":"8","key":"ref10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.5665\/sleep.1150","article-title":"Nighttime Insomnia Symptoms and Perceived Health in the America Insomnia Survey (AIS)","volume":"34","author":"James K. Walsh","year":"2011","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.17m12020","article-title":"Insomnia and Impaired Quality of Life in the United States","volume":"79","author":"Mark Olfson","year":"2018","journal-title":"The Journal of Clinical Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1555-2101","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.1989.03430110069030","article-title":"Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?","volume":"262","author":"D.E. Ford","year":"1989","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"4","key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz007","article-title":"Untreated insomnia increases all-cause health care utilization and costs among Medicare beneficiaries","volume":"42","author":"Emerson M Wickwire","year":"2019","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1378\/chest.14-1617","article-title":"The Pathophysiology of Insomnia","volume":"147","author":"Jessica C. Levenson","year":"2015","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"issue":"4","key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13604","article-title":"Insomnia disorder: State of the science and challenges for the future","volume":"31","author":"Dieter Riemann","year":"2022","journal-title":"Journal of Sleep Research","ISSN":"https:\/\/id.crossref.org\/issn\/0962-1105","issn-type":"print"},{"issue":"5","key":"ref16","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International Classification of Sleep Disorders-Third Edition","volume":"146","author":"Michael J Sateia","year":"2014","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1152\/physrev.00046.2019","article-title":"Brain mechanisms of insomnia: new perspectives on causes and consequences","volume":"101","author":"Eus J. W. van Someren","year":"2021","journal-title":"Physiological Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/0031-9333","issn-type":"print"},{"issue":"4","key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13628","article-title":"Sleep, insomnia and mental health","volume":"31","author":"Laura Palagini","year":"2022","journal-title":"Journal of Sleep Research","ISSN":"https:\/\/id.crossref.org\/issn\/0962-1105","issn-type":"print"},{"issue":"6","key":"ref19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.neuron.2010.11.032","article-title":"Sleep State Switching","volume":"68","author":"Clifford B. Saper","year":"2010","journal-title":"Neuron","ISSN":"https:\/\/id.crossref.org\/issn\/0896-6273","issn-type":"print"},{"issue":"6","key":"ref20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/0748730406294627","article-title":"Neurobiology of the Sleep-Wake Cycle: Sleep Architecture, Circadian Regulation, and Regulatory Feedback","volume":"21","author":"Patrick M. Fuller","year":"2006","journal-title":"Journal of Biological Rhythms","ISSN":"https:\/\/id.crossref.org\/issn\/0748-7304","issn-type":"print"},{"issue":"1","key":"ref21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.smrv.2009.05.002","article-title":"Hyperarousal and insomnia: State of the science","volume":"14","author":"Michael H. Bonnet","year":"2010","journal-title":"Sleep Medicine Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0792","issn-type":"print"},{"issue":"15","key":"ref22","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/nejmcp1412740","article-title":"Insomnia Disorder","volume":"373","author":"John W. Winkelman","year":"2015","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0193-953x(18)30532-x","article-title":"A behavioral perspective on insomnia treatment","volume":"10","author":"Arthur J. Spielman","year":"1987","journal-title":"Psychiatric Clinics of North America","ISSN":"https:\/\/id.crossref.org\/issn\/0193-953X","issn-type":"print"},{"issue":"8","key":"ref24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.5665\/sleep.3916","article-title":"Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomnia","volume":"37","author":"Christopher L. Drake","year":"2014","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"10","key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsx143","article-title":"Familial Risk for Insomnia Is Associated With Abnormal Cortisol Response to Stress","volume":"40","author":"Christopher L Drake","year":"2017","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"11","key":"ref26","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/s41380-018-0033-5","article-title":"Genome-wide analysis of insomnia disorder","volume":"23","author":"Murray B. Stein","year":"2018","journal-title":"Molecular Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1359-4184","issn-type":"print"},{"key":"ref27","isbn-type":"print","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","article-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","ISBN":"https:\/\/id.crossref.org\/isbn\/0890425558"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s0022-3956(02)00052-3","article-title":"Place of chronic insomnia in the course of depressive and anxiety disorders","volume":"37","author":"Maurice M Ohayon","year":"2003","journal-title":"Journal of Psychiatric Research","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3956","issn-type":"print"},{"key":"ref29","article-title":"International classification of sleep disorders","author":"pdf, A. S. D. A. absm. org\/PDF\/ICSD. & 1997, undefined","journal-title":"Revised: diagnostic and coding manual"},{"issue":"4","key":"ref30","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4103\/2249-4863.201153","article-title":"Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities","volume":"5","author":"Swapna Bhaskar","year":"2016","journal-title":"Journal of Family Medicine and Primary Care","ISSN":"https:\/\/id.crossref.org\/issn\/2249-4863","issn-type":"print"},{"issue":"1","key":"ref31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.smrv.2009.09.003","article-title":"Comorbidity of insomnia and depression","volume":"14","author":"Luc Staner","year":"2010","journal-title":"Sleep Medicine Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0792","issn-type":"print"},{"issue":"2","key":"ref32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/sleep\/30.2.213","article-title":"Comorbidity of Chronic Insomnia With Medical Problems","volume":"30","author":"Daniel J. Taylor","year":"2007","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/1550-9109","issn-type":"print"},{"key":"ref33","article-title":"Overview of the treatment of insomnia in adults - UpToDate"},{"issue":"17","key":"ref34","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/archinte.164.17.1888","article-title":"Cognitive Behavior Therapy and Pharmacotherapy for Insomnia: A Randomized Controlled Trial and Direct Comparison","volume":"164","author":"Gregg D. Jacobs","year":"2004","journal-title":"Archives of Internal Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.smrv.2017.02.001","article-title":"Cognitive and behavioral therapies in the treatment of insomnia: A meta-analysis","volume":"38","author":"Annemieke van Straten","year":"2018","journal-title":"Sleep Medicine Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0792","issn-type":"print"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.sleep.2018.05.038","article-title":"Effectiveness of cognitive behavioral therapy for pharmacotherapy-resistant chronic insomnia: a multi-center randomized controlled trial in Japan","volume":"50","author":"Naoko Ayabe","year":"2018","journal-title":"Sleep Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1389-9457","issn-type":"print"},{"issue":"1","key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1163-9","article-title":"Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews","volume":"8","author":"Patricia Rios","year":"2019","journal-title":"Systematic Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/2046-4053","issn-type":"print"},{"issue":"4","key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13604","article-title":"Insomnia disorder: state of the science and challenges for the future","volume":"31","author":"Dieter Riemann","year":"2022","journal-title":"Journal of Sleep Research","ISSN":"https:\/\/id.crossref.org\/issn\/0962-1105","issn-type":"print"},{"issue":"12","key":"ref39","doi-asserted-by":"publisher","first-page":"e1918214","DOI":"10.1001\/jamanetworkopen.2019.18214","article-title":"Pharmacotherapy for Insomnia Disorder in Older Adults","volume":"2","author":"Michael A. Grandner","year":"2019","journal-title":"JAMA Network Open","ISSN":"https:\/\/id.crossref.org\/issn\/2574-3805","issn-type":"print"},{"issue":"3","key":"ref40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","article-title":"Benzodiazepine use, misuse, and abuse: A review","volume":"6","author":"Allison Schmitz","year":"2016","journal-title":"Mental Health Clinician","ISSN":"https:\/\/id.crossref.org\/issn\/2168-9709","issn-type":"print"},{"issue":"7","key":"ref41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/arclin\/acx120","article-title":"The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis","volume":"33","author":"Simon F Crowe","year":"2018","journal-title":"Archives of Clinical Neuropsychology","ISSN":"https:\/\/id.crossref.org\/issn\/1873-5843","issn-type":"print"},{"issue":"5","key":"ref42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2045125317753340","article-title":"Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation","volume":"8","author":"Dimy Fluyau","year":"2018","journal-title":"Therapeutic Advances in Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/2045-1253","issn-type":"print"},{"issue":"3","key":"ref43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder","volume":"87","author":"Yves Dauvilliers","year":"2020","journal-title":"Annals of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"issue":"5","key":"ref44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: First Approval","volume":"82","author":"Anthony Markham","year":"2022","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"issue":"5","key":"ref45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: First Approval","volume":"82","author":"Anthony Markham","year":"2022","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"issue":"21","key":"ref46","doi-asserted-by":"publisher","first-page":"e2287","DOI":"10.1212\/wnl.0000000000009489","article-title":"Daridorexant: A new medication for insomnia in older adults?","volume":"94","author":"Jennifer Rose V. Molano","year":"2020","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref47","article-title":"HIGHLIGHTS OF PRESCRIBING INFORMATION","author":"fda"},{"issue":"2","key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12782","article-title":"Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications","volume":"28","author":"W. Joseph Herring","year":"2019","journal-title":"Journal of Sleep Research","ISSN":"https:\/\/id.crossref.org\/issn\/0962-1105","issn-type":"print"},{"issue":"2","key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12782","article-title":"Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications","volume":"28","author":"W. Joseph Herring","year":"2019","journal-title":"Journal of Sleep Research","ISSN":"https:\/\/id.crossref.org\/issn\/0962-1105","issn-type":"print"},{"issue":"3","key":"ref50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder","volume":"87","author":"Yves Dauvilliers","year":"2020","journal-title":"Annals of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"issue":"10","key":"ref51","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Catherine Roch","year":"2021","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"issue":"10","key":"ref52","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Catherine Roch","year":"2021","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"issue":"6","key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz076","article-title":"Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep\/wake regulation","volume":"42","author":"Carsten Theodor Beuckmann","year":"2019","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"11","key":"ref54","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Clemens Muehlan","year":"2020","journal-title":"Expert Opinion on Drug Metabolism &amp; Toxicology","ISSN":"https:\/\/id.crossref.org\/issn\/1742-5255","issn-type":"print"},{"issue":"10","key":"ref55","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Catherine Roch","year":"2021","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"issue":"1","key":"ref56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Thomas E. Scammell","year":"2011","journal-title":"Annual Review of Pharmacology and Toxicology","ISSN":"https:\/\/id.crossref.org\/issn\/0362-1642","issn-type":"print"},{"key":"ref57","article-title":"Idorsia receives US FDA approval of QUVIVIQ (daridorexant)"},{"issue":"5","key":"ref58","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cpt.1046","article-title":"Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study","volume":"104","author":"Clemens Muehlan","year":"2018","journal-title":"Clinical Pharmacology &amp; Therapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9236","issn-type":"print"},{"issue":"5","key":"ref59","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: First Approval","volume":"82","author":"Anthony Markham","year":"2022","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.37765\/ajmc.2020.42769","article-title":"Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy","volume":"26","author":"J. A. Dopheide","year":"2020","journal-title":"The American Journal of Managed Care","ISSN":"https:\/\/id.crossref.org\/issn\/1936-2692","issn-type":"print"},{"issue":"19","key":"ref61","doi-asserted-by":"publisher","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","article-title":"Orexin A activates locus coeruleus cell firing and increases arousal in the rat","volume":"96","author":"Jim J. Hagan","year":"1999","journal-title":"Proceedings of the National Academy of Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"issue":"2","key":"ref62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0306-4522(01)00512-7","article-title":"Orexins\/hypocretins excite basal forebrain cholinergic neurones","volume":"108","author":"E Eggermann","year":"2001","journal-title":"Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/0306-4522","issn-type":"print"},{"issue":"4","key":"ref63","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Takeshi Sakurai","year":"1998","journal-title":"Cell","ISSN":"https:\/\/id.crossref.org\/issn\/0092-8674","issn-type":"print"},{"issue":"1","key":"ref64","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"L. de Lecea","year":"1998","journal-title":"Proceedings of the National Academy of Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"issue":"4","key":"ref65","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1006\/bbrc.2001.6318","article-title":"Orexins activate histaminergic neurons via the orexin 2 receptor","volume":"290","author":"Akihiro Yamanaka","year":"2002","journal-title":"Biochemical and Biophysical Research Communications","ISSN":"https:\/\/id.crossref.org\/issn\/0006-291X","issn-type":"print"},{"issue":"21","key":"ref66","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.1523\/jneurosci.22-21-09453.2002","article-title":"Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions","volume":"22","author":"Rong-Jian Liu","year":"2002","journal-title":"The Journal of Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/0270-6474","issn-type":"print"},{"issue":"28","key":"ref67","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1523\/jneurosci.1887-05.2005","article-title":"Discharge of identified orexin\/hypocretin neurons across the sleep-waking cycle","volume":"25","author":"M. G. Lee","year":"2005","journal-title":"Journal of Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/0270-6474","issn-type":"print"},{"issue":"3","key":"ref68","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.117.241596","article-title":"The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468","volume":"362","author":"Alexander Treiber","year":"2017","journal-title":"Journal of Pharmacology and Experimental Therapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3565","issn-type":"print"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000514963","article-title":"Hypocretin\/Orexin Receptor Pharmacology and Sleep Phases","volume":"45","author":"Yu Sun","year":"2021","journal-title":"Frontiers of Neurology and Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/1660-4431","issn-type":"print"},{"issue":"23","key":"ref70","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders","volume":"15","author":"Christoph Boss","year":"2020","journal-title":"ChemMedChem","ISSN":"https:\/\/id.crossref.org\/issn\/1860-7179","issn-type":"print"},{"issue":"2","key":"ref71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7326\/m15-2175","article-title":"Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians","volume":"165","author":"Amir Qaseem","year":"2016","journal-title":"Annals of Internal Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"issue":"1","key":"ref72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-14-90","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Anthony L Gotter","year":"2013","journal-title":"BMC Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2202","issn-type":"print"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.peptides.2016.12.008","article-title":"Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms","volume":"88","author":"Shi Tang","year":"2017","journal-title":"Peptides","ISSN":"https:\/\/id.crossref.org\/issn\/0196-9781","issn-type":"print"},{"issue":"21","key":"ref74","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/wnl.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Gary Zammit","year":"2020","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"issue":"3","key":"ref75","doi-asserted-by":"publisher","first-page":"603","DOI":"10.5665\/sleep.5536","article-title":"Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys","volume":"39","author":"Pamela L. Tannenbaum","year":"2016","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/1550-9109","issn-type":"print"},{"issue":"2","key":"ref76","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Catherine Brisbare-Roch","year":"2007","journal-title":"Nature Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1078-8956","issn-type":"print"},{"issue":"1-3","key":"ref77","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejphar.2003.10.007","article-title":"Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance","volume":"482","author":"Jeppe Voss","year":"2003","journal-title":"European Journal of Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"key":"ref78","article-title":"U-90042, a sedative\/hypnotic compound that interacts differentially with the GABAA receptor subtypes - PubMed"},{"issue":"10","key":"ref79","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa080","article-title":"Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial","volume":"43","author":"Thomas C Neylan","year":"2020","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"2","key":"ref80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-010-1933-5","article-title":"Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant","volume":"212","author":"Hendrik Dietrich","year":"2010","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz241","article-title":"The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model","volume":"43","author":"Mackenzie C Gamble","year":"2019","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"2","key":"ref82","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline","volume":"13","author":"Michael J. Sateia","year":"2017","journal-title":"Journal of Clinical Sleep Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1550-9389","issn-type":"print"},{"issue":"11","key":"ref83","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/cmdc.201402258","article-title":"Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1\/orexin 2 receptor antagonist","volume":"9","author":"Christoph Boss","year":"2014","journal-title":"ChemMedChem","ISSN":"https:\/\/id.crossref.org\/issn\/1860-7179","issn-type":"print"},{"issue":"2","key":"ref84","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40271-020-00474-z","article-title":"Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)","volume":"14","author":"Stacie Hudgens","year":"2021","journal-title":"The Patient - Patient-Centered Outcomes Research","ISSN":"https:\/\/id.crossref.org\/issn\/1178-1653","issn-type":"print"},{"issue":"3","key":"ref85","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab224","article-title":"Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem","volume":"45","author":"Mike Ufer","year":"2022","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"2","key":"ref86","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1017\/s1461145712000193","article-title":"The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat","volume":"16","author":"Michel Alexander Steiner","year":"2013","journal-title":"International Journal of Neuropsychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1469-5111","issn-type":"print"},{"key":"ref87","article-title":"Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds - PubMed"},{"issue":"3","key":"ref88","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder","volume":"87","author":"Yves Dauvilliers","year":"2020","journal-title":"Annals of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"issue":"7","key":"ref89","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","article-title":"Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration","volume":"29","author":"Clemens Muehlan","year":"2019","journal-title":"European Neuropsychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"4","key":"ref90","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/1389200220666190206141814","article-title":"Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer\/ Accelerator Mass Spectrometry","volume":"20","author":"Clemens Muehlan","year":"2019","journal-title":"Current Drug Metabolism","ISSN":"https:\/\/id.crossref.org\/issn\/1389-2002","issn-type":"print"},{"issue":"8","key":"ref91","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40261-021-01062-1","article-title":"Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis","volume":"41","author":"Uta Schilling","year":"2021","journal-title":"Clinical Drug Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/1173-2563","issn-type":"print"},{"issue":"6","key":"ref92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsaa275","article-title":"Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea","volume":"44","author":"Marie-Laure Boof","year":"2021","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"5","key":"ref93","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: First Approval","volume":"82","author":"Anthony Markham","year":"2022","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"issue":"2","key":"ref94","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bcp.15029","article-title":"Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist","volume":"88","author":"Martine Gehin","year":"2022","journal-title":"British Journal of Clinical Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0306-5251","issn-type":"print"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.euroneuro.2021.05.005","article-title":"Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects","volume":"51","author":"Benjamin Berger","year":"2021","journal-title":"European Neuropsychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"11","key":"ref96","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/1440-1681.13370","article-title":"The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin","volume":"47","author":"Isabelle Zenklusen","year":"2020","journal-title":"Clinical and Experimental Pharmacology and Physiology","ISSN":"https:\/\/id.crossref.org\/issn\/0305-1870","issn-type":"print"},{"issue":"12","key":"ref97","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s40263-020-00768-8","article-title":"Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects","volume":"34","author":"Benjamin Berger","year":"2020","journal-title":"CNS Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1172-7047","issn-type":"print"},{"issue":"10","key":"ref98","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40262-021-01028-8","article-title":"Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist","volume":"60","author":"Benjamin Berger","year":"2021","journal-title":"Clinical Pharmacokinetics","ISSN":"https:\/\/id.crossref.org\/issn\/0312-5963","issn-type":"print"},{"issue":"6","key":"ref99","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/cts.13079","article-title":"Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment","volume":"14","author":"Benjamin Berger","year":"2021","journal-title":"Clinical and Translational Science","ISSN":"https:\/\/id.crossref.org\/issn\/1752-8054","issn-type":"print"},{"issue":"3","key":"ref100","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab224","article-title":"Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem","volume":"45","author":"Mike Ufer","year":"2022","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"2","key":"ref101","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Emmanuel Mignot","year":"2022","journal-title":"The Lancet Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1474-4422","issn-type":"print"},{"issue":"4","key":"ref102","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1111\/jsr.13248","article-title":"Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease","volume":"30","author":"Marie-Laure Boof","year":"2021","journal-title":"Journal of Sleep Research","ISSN":"https:\/\/id.crossref.org\/issn\/0962-1105","issn-type":"print"},{"issue":"3","key":"ref103","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder","volume":"87","author":"Yves Dauvilliers","year":"2020","journal-title":"Annals of Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"issue":"6","key":"ref104","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.biopsych.2010.10.023","article-title":"Prevalence and Perceived Health Associated with Insomnia Based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria\/International Classification of Sleep Disorders, Second Edition Criteria: Results from the America Insomnia Survey","volume":"69","author":"Thomas Roth","year":"2011","journal-title":"Biological Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"}],"container-title":["Health Psychology Research"],"original-title":[],"link":[{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/2025040616244115a684040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/2025040616244115a684040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T03:10:51Z","timestamp":1760411451000},"score":1,"resource":{"primary":{"URL":"https:\/\/healthpr.org\/journal\/HPR\/10\/3\/10.52965\/001c.37400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":104,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,8,20]]}},"URL":"https:\/\/doi.org\/10.52965\/001c.37400","relation":{},"ISSN":["2420-8124"],"issn-type":[{"value":"2420-8124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]}}}